SALT LAKE CITY, UT -- (MARKET WIRE) -- May 15, 2007 -- Myriad Genetics, Inc. (NASDAQ: MYGN) reported today that a new study has estimated the potential savings to the United States healthcare system, from a disease-modifying Alzheimer's drug, at up to $4.0 trillion. These savings would be for new cases arising between 2010, when the first such drug is estimated by the authors to be available, and 2050, when the number of Alzheimer's disease sufferers could reach its peak.
